International deal for Phylogica
SUBIACO-BASED drug discovery firm Phylogica has announced an agreement with Europe’s largest pharmaceutical company, Roche, to evaluate the firm’s disease-attacking technology.
Phylogica has the intellectual property rights to a unique collection of proteins called phylomers, which are focused on developing therapies for the treatment of inflammatory diseases such as asthma, acute stroke damage, and diabetes.
I'd like to register please
8 free articles per month + business email alerts twice daily
us on +61 8 9288 2100 during WST office hours